SCHEMBL30078221

SCHEMBL30078221

Cc1ccc(NC(=O)OC(C)(C)C)cc1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA9 Q16790 1/20 0.54
MAP4K4 O95819 1/20 0.47
CYP17A1 P05093 2/20 0.44
MAPKAPK2 P49137 3/20 0.44
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PSMB8 P28062 1/20 0.42
NAMPT P43490 1/20 0.42
CFTR P13569 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714227 1.00 CA12 (0.54) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL707247 0.88 CA12 (0.54) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL29425603 0.88 CA12 (0.54) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL13624134 0.87 CA12 (0.50) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL13197992 0.85 CA12 (0.58) CA12CA1CA9CYP17A1ALDH1A1
SCHEMBL23033538 0.84 CA12 (0.48) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL31314406 0.83 SMN1; SMN2 (0.52) ALDH1A1MAPTTDP1CFTRMEN1
SCHEMBL10782684 0.83 SMN1; SMN2 (0.52) ALDH1A1MAPTTDP1CFTRMEN1
SCHEMBL397557 0.83 CA12 (0.47) CA12CA1CA9MAP4K4CYP17A1
SCHEMBL4013659 0.83 NPC1 (0.59) CA12CA1CA9MAP4K4CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676600-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF Deliver Therapeutics, Inc. (US) 2026-01-14 EP disclosed
EP-4676601-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF Deliver Therapeutics, Inc. (US) 2026-01-14 EP disclosed
US-20240400577-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC 2024-12-05 US disclosed
WO-2024186579-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF DELIVER THERAPEUTICS, INC. (US) 2024-09-12 WO disclosed
WO-2024186580-A1 PROTEIN KINASE INHIBITORS AND USES THEREOF DELIVER THERAPEUTICS, INC. (US) 2024-09-12 WO disclosed
WO-2024158872-A1 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF THE ROCKEFELLER UNIVERSITY (US) 2024-08-02 WO disclosed
WO-2023247593-A1 PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 WO disclosed
WO-2023183470-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC (US) 2023-09-28 WO disclosed
WO-2023283369-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400577-A1 MODULATORS OF PROTEIN KINASES MAP3K20, PRKCE, PRKCH CA12 4818/4885CA1 4778/4885CA9 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.